1p 1416

3-phosphoinositide-dependent protein kinase-1 14653D tumour model 194

5-fluorouracil 334, 910, 1028, 15325-FU 919

adaptive conjoint analysis 717adenomatous polyposis coli 384adenosarcoma 1194adenovirus 992adjuvant chemotherapy 1021adjuvant therapy 654adjuvant; neutropaenia 1642adolescent 29adrenal tumour 420adult T-cell leukaemia 1099advanced cancer 177, 1475advanced ovarian cancer 1200aerobic glycolysis 646aetiology 1287, 1291Affymetrix 1165

ageing 1189AKT 218, 785, 809albumin 1266alcohol 118alcohol consumption 1287alcohol intake 700alcoholic beverages 429alkaline sphingomyelinase 1441ALL 992allelic imbalance 1157AML 877anastrozole 152androgen-independent 1206androgens 688androstene neuro-steroids 619aneuploidy 1218angiogenesis 391, 513, 1277, 1432, 1523, 1673angiopoietin family 877anilinoquinazolines 183anti-adhesion 730anti-EGFR treatment options 92anti-folates 1071antiangiogenic 65anticancer agent 1344antigen shedding 1146antihypertensive treatment 112antimetabolites 628anxiety 1625APC antibody specificity 384apoptosis 253, 277, 637, 769, 902, 1077, 1225, 1234, 1432, 1532, 1696aromatase 755aromatase inhibitor 152array-CGH 260asbestos 1300aspirin 1295attributable proportion 129audiovisual patient information 705Aurora-A 1664autologous transplantation 539awareness 691AZD2171 65

B-CLL 769basement membrane 1505BCG-refractory 1499Bfl-1 769biliary tract cancer 1577biochemical recurrence 678biomarker 1, 1457biopsy 952bladder cancer 1499blood outgrowth endothelial cell 513blood pressure 112blood testing 1399blood–brain barrier 322body mass 1486body mass index 995, 1005bone metastasis 964bone tumours 1588bone turnover 964bortezomib 1099brain tumour 1583BRCA2 gene 826breast 1642, 1673breast and bladder cancer 502breast cancer 58, 105, 152, 327, 434, 440, 479, 654, 686, 688, 725, 761, 809, 832, 957, 964, 978, 1046, 1090, 1157, 1175, 1211, 1251, 1277, 1287, 1361, 1372, 1505, 1523, 1570, 1625, 1632breast cancer susceptibility 1696breast conservation 883breast surgery 1211breast-conserving surgery (BCS) 725breast-conserving treatment 1046

[11C]carvedilol 322c-Kit 857c-MET 368C-reactive protein 1266C4.4A 1146C6 cells 755Ca2+-binding protein 792

cancer clinical trials 705cancer mortality 1300cancer services 1588cancer survivors 612cancer survivorship 1625cancer testis antigen 543cancer vaccine 1381capecitabine 712, 862, 1333, 1475carbonic anhydrases 1465carboplatin 162carcinogenesis 646carcinoma of an unknown primitive 857cardiotoxicity 1084case–control study 429, 434, 995caspases 1234CCR7 670CD9 941CDK4 1242CEA 745celecoxib 1206cell cycle 277, 1513cell cycle checkpoints 1664cell death 1381cell migration 1361, 1432cell-free DNA 1399cell-of-origin subtypes 1165central nervous system tumours 1588cervical cancer 129, 133, 218, 1322, 1457cervical carcinoma 1058cervix carcinoma 1135CESH 1707cetuximab 494, 1139CGH 238chemokine receptor 670chemoprevention 327chemoradiotherapy 712, 883chemoresistance 769chemotherapy 29, 862, 1028, 1040, 1157, 1234, 1642Chernobyl 818childhood 1583childhood acute lymphoblastic leukaemia 140childhood cancer 412, 695, 986childhood leukaemia 986, 1009, 1315Chile 85China 123, 1577Chlamydia 949cholecystitis 1577chromosomal instability 1218chromosome 1696, 1707chronic lymphocytic leukaemia 253cigarette smoking 700circumferential resection margin 1333cisplatin 162, 194, 712, 851, 1234, 1329clear cell adenocarcinoma 1053clear cell renal cell carcinoma 420clinical decision support systems 486clinical phase II study 1084clonality 1260coffee 426, 1291cognitive behaviour therapy 612cohort 686, 1295, 1570cohort studies 115, 118, 123, 129, 426, 1005, 1291, 1300collagen I 358colon cancer 1021, 1655colorectal 971colorectal adenoma 1425, 1449colorectal cancer 297, 446, 745, 978, 1028, 1035, 1139, 1146, 1266, 1305, 1425, 1486, 1606colorectal cancer cells 384colorectal neoplasms 118, 1393, 1601colorectal tumours 92combination index 628combination treatments 888communication skills 472comparative genomic hybridisation 1707computer simulation 1322conformal radiation 464convection 194copper transporter ATP7A 334cost-effectiveness analysis 152, 1322cost-utility analysis 152Costa Rica 837costs 479COX-2 inhibitor 1206COX2 557coxibs 1465CRH 637CS-682 628CXCL12 761CXCR4 761cyclooxygenase-2 1388, 1523cyclooxygenase-2 independence 1465cyclophosphamide 1200CYP3A4 metabolism 440cytokines 105, 210cytotoxic T lymphocyte 1648, 1655

DDS 170deep-vein thrombosis 1053degradome 201degranulating CD8+ cells 1381dendritic cells 1251depression 1625deprivation 999detection methods 1632diabetes 995Dickkopf-1 964dietary iron 118diffusion 194disease progression 1469disease-free survival 50Dkk-1 1552DNA crosslinking 253, 927DNA damage 1189DNA hypomethylation 412DNA methylation 895, 1457DNA repair 334, 927docetaxel 290, 593, 851, 1206, 1338, 1475, 1613doctor discipline 6doctor specialty 6dose intensity 1642dose-limiting toxicity 177downstaging 851doxorubicin 43, 1084doxorubicin resistance 1077drug delivery 194, 735, 910drug development 577drug resistance 562, 927, 1218ductal carcinoma in situ (DCIS) 725dynamic models 1322dysplasia 1545

E-cadherin 358E2F 1242early-onset disease 826EBV 1567EGFR 453, 494, 659, 778, 857, 1139, 1560EGFR downstream signalling pathway 92EGFR mutations 1560elderly 162, 1606ELISA 398embryonic tumours 412endometrial 1194endometrial cancer 995, 1538

endoplasmic reticulum (ER) stress 1465endoscopy 1493endostatin 513endovesical instillation 1499England 989ENPP7 1441EpCAM (CD326) 315epidemiology 112, 1287, 1583epidermal growth factor receptor mutation 741epidermoid cancer 1234epigenetic process 1116epigenetics 1, 267, 562, 986, 1416epirubicin 1200ErbB2 659, 1354ErbB2 mutation 741ErbB3 453ESCC 1409esophageal cancer 218estramustine 1206, 1613etoposide 162expectations 14extracellular matrix 201

α-fetoprotein 327FACS 73faecal occult blood 1601familial 1175Fas ligand 637FASL 73fatigue 612FDG-PET 902, 1493female 989fetal origins of disease 686fibroblasts 210, 398first-line treatment 297fluorescent in situ hybridisation 1139foetal haemoglobin 412folate 1449folate metabolism 247FOLFIRI 1035follow-up 1632

G1 phase 1242galectin-3 1146gallstones 1577GAMEC 308gastric 902gastric adenocarcinoma 458gastric cancer 37, 123, 543, 550, 589, 700, 712, 837, 851, 1493, 1567gastric cancer screening 837gastric carcinoma 334GDEPT 745gefitinib 65, 183, 778, 1560gemcitabine 43, 145, 283, 464, 1329, 1499gene expression 145, 895gene expression profiling 1432gene fusion 1690gene therapy 513genetic alterations 260genetic susceptibility 1701genetics 1305genomics 1116germ cell 308glioblastoma 302, 619glioma cells 755glucose transport 902glucose-regulated protein 94 kDa 792GLUT-1 646glycosaminoglycan 761glycosylation 1146grapefruit intake 440GSTP1 1399Guthrie cards 992

haematological malignancies 1588haeme oxygenase-1 1683haplotype 832HCC 1399HCV 1399HDAC 1344HDAC inhibitor 177, 1344head and neck cancer 65, 670hemangiosarcoma 115heme iron 118heme oxygenase-1 1099hepatic resection 1606hepatitis C virus 426hepatocellular carcinoma (HCC) 50, 426, 582, 862, 1260, 1532HepG2 1441HER dimerisation inhibitors 1338HER-2 105, 494Her-2/neu overexpression 857HER2 453HER3 453hereditary 486hetastatic breast cancer 1040hexokinase 902high dose 308high-dose chemotherapy 391, 1200high-risk breast cancer 391histone modifications 1histopathology 1393HLA-A3 supertype 1648HMEC 1361Hodgkin lymphoma 29Hodgkin's 1310homocysteine 1071hormonal 1194hormone refractory 378hormone replacement therapy 118, 1486hormone-refractory 1480hormones 688HPV 218HPV infection 133HPV vaccination 1322HRQOL scores 302Hsp90 741human 992, 1441human gastric cancer 895human papillomavirus 85, 691hypercalcaemia 183hypericin 502hypermethylation 267hypertension 995hypomethylation 267hypoxia 646

IBC signature 1165Id proteins 1409IL-6 378IL-6R 378imatinib 735immune function 1251immune privilege 637immunohistochemistry 398, 405, 523, 531, 1135, 1404immunostaining 952immunotherapy 210, 315, 598, 1354immunotherapy CD40 1251impact evaluation 837improvement 1469incidence 1009, 1567individual dosing 290indomethacin 1077infection 1310inflammatory breast cancer 659, 883inhibitor of apoptosis 1271insulin 98insulin-like growth factor 98insulin-like growth factor binding protein 98integration 85integrins 1090interferon resistance 231interferon-γ 420interleukin-6 1513international differences 1277interphase FISH 678interstitial fluid pressure 735intervention 612invasion 73, 358, 368, 1505invasiveness 50ionising radiation 1664irinotecan 297, 593, 1035irradiaton 322isolated tumour cells 589

JAK 378JNJ-16241199 1344

K-Ras 1139K-ras/BRAF mutations 1425Ki-67 1124KIF2C 543kinase inhibition 741knowledge 691, 705

Lactobacillus rhamnosus GG 1028late complication 1058Lck 1648left-handedness 686letrozole 802leucovorin 297leukocytes 978lifestyle factors 133ligand interactions 1361liver cancer 1005liver diseases 1441liver metastases 1035liver tumour 1441Livin/ML-IAP/KIAP 1271local recurrence 1046locally advanced 464locally advanced rectal cancer 1333locoregional relapse 1632long-term effect 612loss of heterozygosity 1157lung cancer 183, 247, 735, 1295, 1300lung carcinoma 85lymphadenectomy 1194lymphoma 539, 619, 1310

malignant glioma 619malignant melanoma 231mammary carcinoma 1354marker 1545Masaoka's staging system 22mass screening 1601mast cells 952maternal 688mathematical models 646, 1322matrikine 1505matrix metalloprotease 1106matrix metalloproteinase 398, 971, 1505maximum tolerated dose 177MCAK 543MCM-2 1124MCM-5 1124MDA-MB-231 1361medical education 472medulloblastoma 267melanoma 223, 1225, 1329melatonin 755mesenchymal stem cell 1552mesothelioma 1300meta-analysis 1005, 1291metastases 868, 1606metastasis 223, 670, 761, 957, 1409, 1523metastatic gastric cancer 593methotrexate 308methylation 1425microarray 818microdose 577micrometastasis 550micronuclei 1218microtubule 1218, 1673microtubule inhibitors 888microvessel density 391, 405, 1277midkine 405migration 543, 1090minimum dataset 1393mitochondria 345mitogen-activated protein kinase 659mitomycin 1475mitotic catastrophe 941mitoxantrone 1613MMP 957modulation 919molar pregnancy 986monoHER 1084monohydroxyethylrutoside 1084monounsaturated fat 1570morphine 1523mortalin 941mortality 1009mortality trends 1588motility 358MRP1 1077MS-MLPA 1457Ms-SNuPE 1457MSC 1552MSP 1457MT1-MMP 358MUC-1 730MUC1 O-glycosylation 910MUC4 345mucin 345multicell layer 194multicentric occurrence 1260multidrug resistance 502, 934multifocal low-grade urothelial cancer 260mutation 778, 1416Mycoplasma 949

N-acetylglucosaminyltransferase V 1538natural killer cells 539neoadjuvant 1035neoadjuvant chemoradiotherapy 1333neoadjuvant chemotherapy 589neoplastic syndromes 486nested case–control study 426, 446neuroblastoma 210, 238, 1416neuron-glia-related cell-adhesion molecule 531neuropilins 1090neutropenia 37NF-κB 523, 745, 1165NF-κB 659NHE 646NK cytotoxicity 105NK105 170non-small-cell lung cancer 283, 741NSAIDs 557NSCLC 1560nuclear localisation 1683nucleoside analogue 628nucleoside diphosphate kinase 1372

obesity 1005occupational exposure 1300octreotide 582oesophageal cancer 123, 494, 868oesophagus 1404oestrogen receptor 58, 659offspring gender 688oncogenes 1189oncology 472, 1063opioids 1523OPN 1545oral squamous cell carcinoma 792osteonectin 1106osteosarcoma 1552outcome 1632ovarian adenocarcinomas 1124ovarian cancer 358, 637, 927, 1053, 1618ovarian low malignant potential tumours 1124ovarian neoplasms 1291overall response rate 1618overrepresentation analysis 1432oxaliplatin 593, 862oxaliplatin resistance 334oxidative stress 1683

P-glycoprotein 322, 934p16INK4A 1242P2Y receptors 1372p53 58, 1225, 1532, 1664paclitaxel 43, 170, 888, 1218palliative 283palliative care 472pancreas cancer 464pancreatic adenocarcinoma 598, 1106pancreatic cancer 98, 345, 910, 1432pancreatic carcinoma 405, 523pancreatic neoplasms 1116pangenomic analysis 238panitumumab 1469papillary thyroid carcinoma 531papillomavirus 129papillomavirus, human 989parental occupation 1315passive smoking 434pathology 654pathway analysis 792patient recruitment 705patient-centred assessment 1063patient-reported outcomes 1469PBD dimer 253PDK-1 785pegylated interferon 1532pemetrexed 1071peptides 1648, 1655performance status 458pericellular proteolysis 201peritoneal dissemination 550pertuzumab 1338PHA680632 1664pharmacodynamic markers 1071pharmacodynamics 290, 577pharmacogenomics 145pharmacokinetics 43, 290, 577phase 0 trial 577phase I 844, 1338phase I study 170phase I/II study 712phase II clinical trial 862phase II study 1480phosphorylated Akt 92phosphorylated MAPK 92photochemical internalisation 502photodynamic therapy 502, 1381, 1513physical activity 995PI3K/Akt 453PIK3CD 1416pineal 755plasma 25-hydroxyvitamin D 446plasma D-dimer 1053plasma deoxynucleosides 1071platelets 978platinum chemotherapy 927platinum-resistant 1618platinum-sensitive 1618PLD1 809polymer micelles 170polymorphisms 145, 557, 1175, 1449polyphenolic compounds 1372polyunsaturated fat 1570poor prognosis 792poor-risk 162population analysis 290population dynamics 140population study 29, 112population-based 730population-based cohort study 986positive lymph nodes 605post-cancer fatigue 612postmenopausal 1486postnatal vasculogenesis 513poverty 140PPAR 1388predicting factor 405predisposition 1305preeclampsia 688premenopausal 802prenatal infection 992preoperative 802primary colon cancer cells 73primary health care 486primary therapy 802probiotic 1028profilin 1361prognosis 1, 37, 238, 247, 523, 550, 957, 1211, 1409, 1690prognostic biomarker 678, 877prognostic factors 302, 391, 605, 952, 1538prognostic marker 730programmed cell death 619progression-free survival (PFS) 1538, 1618proline-rich tyrosine kinase2 (Pyk2) 50promoter 277promoter hypermethylation 1260prostate 378, 941, 1673prostate cancer 557, 730, 826, 952, 978, 1206, 1480, 1613, 1683prostatic neoplasms 1690proteasome inhibitor 1099protein-truncating BRCA2 mutations 826proteomics 1116PSA 678psychosocial 1063PTEN 1139PTEN haploinsufficiency 678PTHrP 183public 691pulmonary MALT lymphoma 949pulmonary thromboembolism 1053

quality of life 283, 1469, 1625quantitative RT–PCR 531

R306465 1344race 14, 140radiation 1058, 1505radiation effects 115radiation susceptibility 818radiosensitivity 1696radiotherapy (RT) 65, 115, 725randomised controlled trials 486randomised trial 1200rapamycin 809Ras signalling pathway 1425RASSF2 1425real-time methylation specific PCR 1260real-time PCR 1399recurrence 50, 479red meat 118RelA 523relative survival 999renal cell cancer 112, 429renal cell carcinoma 1271resistance 919review 1005rhabdomyosarcoma 785risk 971, 1486

S-1 37, 458, 851S100 267S6 kinase 218sarcoma 115, 1194saturated fat 1570SCC 1545SCLC 1077Scotland 999screen-detected 725screening 129, 971, 1493second cancer 1058second soft tissue sarcoma 695SEER-Medicare 1606self-report 14senescence 941, 1225sensitivity 1493sequential chemotherapy 1613seroepidemiologic studies 989serum 778, 978sex 140SFRPs 895shared decision-making 6signal transduction 368single nucleotide polymorphism 832siRNA 384SJG-136 253skin reactions 14Smad-pathway 1388small cell lung cancer 368small molecular inhibitor 785small molecule 1344small-cell lung cancer 162smoking 434, 1287SNP 247social contact 1315social difficulties 1063socioeconomic inequalities 999socioeconomic status 140SOCS proteins 231solid tumours 539, 844soluble interleukin-6 receptor 1513somatostatin analogues 582sorafenib 1480spermatocytic seminoma 1707splice 277sporadic 1175squamous cell carcinoma 1404St Gallen expert consensus meeting 654stage II 1021staging 868, 1393STAT 378STAT phosphorylation 231stealth liposome 919stellate cells 1106stem cells 1189stereology 1135stromal 1194subsite 700superoxide dismutase 2 1116surgery 1690survival 283, 523, 670, 1124, 1266, 1567symptom 1469synergy 253, 628synthetic vectors 210

T-cell signalling proteins 105tailor-made therapy 145tamoxifen 152, 327, 582tea 1291teenage and young adult cancer 1588telomere 832, 1696temozolomide 1225TERF2 832TERT 832testicular germ cell tumour 1701, 1707testicular microlithiasis 1701TGF-α 1388TGF-β signal 1388the Sloane Project 725three weekly schedule 1040thymic epithelial tumour (TET) 22thymidine phosphorylase 745thymidylate synthase 334, 1242, 1449thymidylate synthase inhibition 1071thyroid cancers 818time-dependent variable 37TIMP 957tissue microarray 785titanocene 1234TMX2-28 cells 809TNM stage 1266toll-like receptor 598tonsil 670topoisomerase II 58total dietary fat 1570toxicity 577, 712TP53 1157trabectedin 1618TRAIL 73transcription 277transformation 1457transforming growth factor-β 398, 1106transforming growth factor-β receptor 1 1175trastuzumab 494treatment 14treatment decisions 6treatment outcomes 717treatment preference 717treatment tradeoff method 717trends 1009treosulfan 1329trichostatin A 562trifunctional antibodies 315tumour 277, 513tumour angiogenesis 1372tumour immunity 1655tumour infiltrating lymphocytes 1135tumour marker 412tumour microenvironment 398, 1106tumour therapy 1271tumoural invasion 957twenty year follow-up 730tyrosine kinase inhibitor 65, 453tyrosine kinase receptor 857

UFT 297undergraduate 472understanding 705urbanisation 140uterine cancer 605

valproic acid 177vascular disrupting 888vascular endothelial growth factor 391VEGF 851VEGF family 877VEGF-C 1090VEGF165b 223VEGFxxxb 223vinorelbine 283viral load 85vitamin D 123

weekly docetaxel 1040weekly epirubicin 1040weekly schedule 1040western blot 531white cells 1266WHO histologic classification 22Wnt signalling 964women 1295wound healing 1211

X-ray 1583xanafide 58XELOX 862xenografts 73, 919XR5944.14 844

young age 1046

ZD1839 183ZD6126 888ZD6474 934